[ad_1]
Explore how the innovative pharmaceutical industry is partnering to ensure innovation and access contribute to global health progress and improve lives everywhere in this report.
The Sustainable Development Goals (SDGs) explicitly strive to engage the private sector in addressing the world’s most pressing challenges and emphasize the importance of cross-sector collaborations. Universal Health Coverage (UHC) is at the heart of the health-related SDGs and the foundation for improving health and well-being for all people at all ages, and for global health security
The private sector, as significant providers of health products and services, makes vital contributions to advance UHC and health security. It is a leader in innovation and new products, techniques, and insights that can improve health care, strengthen health systems, and increase efficiencies
The innovative pharmaceutical industry plays a unique role in driving innovation and is part of the solution toward global efforts to achieve UHC. It supports the efforts of governments and other stakeholders to provide the necessary enabling environments, including through:
- Building health system readiness and resilience together with a life-course approach
- Investing more and investing better to achieve and uphold quality UHC
- Supporting collective public-private collaborations to accelerate progress.
UHC2030 private sector constituency 5 commitments
UHC2030 represents a cross-sectoral platform encompassing civil society, governments, and the private sector. As long-term partners in the UHC2030 movement, and as part of the UHC2030 Private Sector Constituency (PSC), IFPMA and our members reiterate the innovative pharmaceutical industry’s commitments to contribute to UHC.
Together with other global health stakeholders, the innovative pharmaceutical industry works to improve health and well-being for all people at all ages and strengthen global health security that serves us all.
The case studies in this report include examples of IFPMA members’ innovative approaches to R&D and product development as well as innovative access, product supply, and healthcare delivery models, in line with UHC 2030’s PSC statement.
[ad_2]
Source link
